Morgan Stanley lowered the firm’s price target on Inspire Medical (INSP) to $182 from $200 and keeps an Overweight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $149 from $176 at Leerink
- Inspire Medical granted premarket application approval for CGuard Prime
- Buy Recommendation for Inspire Medical Systems Driven by Efficiency and Growth Potential
- Inspire Medical Systems Launches Inspire V for OSA
- Inspire Medical Systems: Poised for Growth with Inspire 5 and SleepSync Adoption